Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CEVEC Pharmaceuticals and South Korea-based Yuhan have signed a CAP-Technology license agreement, enabling Yuhan to utilize CEVEC's CAP-T and CAP cell expression systems to produce and develop a variety of therapeutic proteins.
Subscribe to our email newsletter
CAP-T CAP cells, which are immortalized cell lines, produce transient and stable protein.
The CAP Technology allows for superior protein yields in a shorter time than traditional methods, according to CEVEC.
CEVEC CEO Wolfgang Kintzel said, ”We’re very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules.”
Yuhan Research Institute Bio-Innovation unit head Jong-Gyun Kim said, ”We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."